Recent pan-cancer analysis revealed that FDX1 could be a novel biomarker in the prognosis and immunotherapy in human tumors, which could provide a basis for drug use in certain tumors (Ma et al., 2022; Zhang et al., 2022). Here, FDX1 is linked to cancer.